Biogen (NASDAQ:BIIB) Releases FY 2025 Earnings Guidance

Biogen (NASDAQ:BIIB) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 15.250-16.250 for the period, compared to the consensus EPS estimate of 16.240. The company issued revenue guidance of -.

Biogen Stock Down 5.1 %

NASDAQ BIIB traded down $7.13 during mid-day trading on Wednesday, reaching $132.27. 1,511,555 shares of the company’s stock traded hands, compared to its average volume of 1,301,840. Biogen has a 1-year low of $128.51 and a 1-year high of $238.00. The company has a fifty day simple moving average of $148.28 and a 200-day simple moving average of $174.33. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The company has a market cap of $19.27 billion, a price-to-earnings ratio of 11.95, a P/E/G ratio of 1.65 and a beta of -0.08.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%. As a group, equities research analysts expect that Biogen will post 16.42 EPS for the current year.

Wall Street Analysts Forecast Growth

BIIB has been the topic of several recent research reports. Oppenheimer cut their price target on Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Stifel Nicolaus downgraded Biogen from a “buy” rating to a “hold” rating and set a $175.00 price target on the stock. in a report on Monday, December 16th. William Blair reissued an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Citigroup cut their price target on Biogen from $190.00 to $160.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Wolfe Research initiated coverage on Biogen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Seventeen investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Biogen currently has an average rating of “Hold” and an average target price of $221.65.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.